Repeatability in Hyperpolarized 3-Helium With MRI

Phase 4

Completed

Interventions: Drug: Supine hyperpolarized 3 helium gas scan
Drug: Prone hyperpolarized 3 helium gas scan
Diagnostic Test: Vitals
Diagnostic Test: Pulmonary Function Tests
Diagnostic Test: Initial protocol MRI scan

Brief Summary: The main purpose of this study is to assess and test the reproducibility and results of hyperpolarized 3-Helium gas as a contrast agent with Magnetic Resonance Imaging (MRI) of the lungs in healthy adult subjects.

Detailed Description: New CT imaging techniques often expose the patient to higher doses of radiation. There is a great deal of concern about effects of medical radiation exposure on the general public and regulations are becoming stricter on the radiation doses that are allowed.

One novel procedure that has been developed to evaluate the function and structure of the lung is the use of hyperpolarized gases with MRI scanners. We want to compare the lung imaging techniques that we have developed in our lab to a technique that uses hyperpolarized 3-Helium gas with MRI. This technique is free from radiation and less invasive than many lung imaging techniques.

Hyperpolarized gas MRI is based on the introduction of spins into the lungs, allowing imaging to take place. The use of hyperpolarized 3-Helium has a few advantages:

1. it allows us to see the microstructure of the lungs through diffusion imaging (apparent diffusion coefficient) which correlates with the size of airways and alveolar space.

2. it allows us to see ventilation, or how air moves in the lungs, at a high resolution.

3. it is capable of ultra fast imaging which will help us assess gas flow patterns within the airways.

and 4) the speed of depolarization lets us measure the partial pressure of oxygen and associated gas exchange mechanisms.

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

if female, must not be pregnant or breastfeeding
must not have any metal objects in or on their body including body piercings that cannot be easily removed, bullets, metallic fragments or slivers in eyes, skin, etc., pacemaker or defibrillation, aneurysm clips, cochlear implants, coronary stents, or neurostimulation.
must not have a history of claustrophobia, panic disorders, anxiety attacks, atrial fibrillation, uncontrolled high blood pressure, frequent ventricular ectopic rhythm, hemodynamic instability, kidney dysfunction or heart disease.

Arm && Interventions

Group	Intervention	Description
Group One: Prone MRI Scans	Vitals	Subjects will have vitals, pulmonary function tests, initial proton MRI scan, prone hyperpolarized 3 helium gas scan
Group One: Prone MRI Scans	Pulmonary Function Tests	Subjects will have vitals, pulmonary function tests, initial proton MRI scan, prone hyperpolarized 3 helium gas scan
Group One: Prone MRI Scans	Initial protocol MRI scan	Subjects will have vitals, pulmonary function tests, initial proton MRI scan, prone hyperpolarized 3 helium gas scan
Group Two: Supine MRI scans	Supine hyperpolarized 3 helium gas scan	Subjects will have vitals, pulmonary function tests, initial protocol MRI scan, supine hyperpolarized 3 helium gas scan
Group Two: Supine MRI scans	Vitals	Subjects will have vitals, pulmonary function tests, initial protocol MRI scan, supine hyperpolarized 3 helium gas scan
Group One: Prone MRI Scans	Prone hyperpolarized 3 helium gas scan	Subjects will have vitals, pulmonary function tests, initial proton MRI scan, prone hyperpolarized 3 helium gas scan
Group Two: Supine MRI scans	Pulmonary Function Tests	Subjects will have vitals, pulmonary function tests, initial protocol MRI scan, supine hyperpolarized 3 helium gas scan
Group Two: Supine MRI scans	Initial protocol MRI scan	Subjects will have vitals, pulmonary function tests, initial protocol MRI scan, supine hyperpolarized 3 helium gas scan

Primary Outcome Measures

Name	Time	Method
Apparent Diffusion Coefficient (ADC) as a Function of Lung Inflation Levels.	Through study completion, measurements completed at one day visit only.	Validate the intrinsic variability of ADC (cm2/s) as a function of normal procedural and physiological changes in an attempt to standardize the use of the biomarker in future assessments of pulmonary pathologies.

Secondary Outcome Measures